Dr Chava Rena Markowitz, AUD CCC-A | |
225 N Wood Ave, Linden, NJ 07036-4200 | |
(908) 583-5284 | |
Not Available |
Full Name | Dr Chava Rena Markowitz |
---|---|
Gender | Female |
Speciality | Audiologist |
Location | 225 N Wood Ave, Linden, New Jersey |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1821644857 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
231H00000X | Audiologist | 41YA00105900 (New Jersey) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Chava Rena Markowitz, AUD CCC-A 225 N Wood Ave, Linden, NJ 07036-4200 Ph: () - | Dr Chava Rena Markowitz, AUD CCC-A 225 N Wood Ave, Linden, NJ 07036-4200 Ph: (908) 583-5284 |
News Archive
As Pisgah Laboratories, Inc. continues development of its lead abuse deterrent opioid product, it will soon begin scale-up of its patent-pending form of hydrocodone. Pisgah has developed a specialized salt form of hydrocodone which imparts abuse deterrent properties to a dosage product. Pisgah will manufacture its hydrocodone salt for clinical trials in their FDA / DEA registered facility.
The Washington Post as part of a four-day series, titled "Careless Detention," is examining how some immigrants to the U.S. do not receive needed health care while in immigration detention centers.
Precision Therapeutics will proudly continue its dedicated support to the NOCC Pittsburgh Chapter's 13th Annual Walk to Break the Silence on Ovarian Cancer. Precision has been a strong supporter of the NOCC 5 Mile Run/5 Mile & 1 Mile walk for over five years, and once again expects a great number of its employees will join together in full force to walk alongside ovarian cancer patients and survivors to help strengthen the partnerships it has forged by supporting the very cancer patients that it strives to help.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preclinical data which demonstrate that its Notch1-specific monoclonal antibody is a highly potent inhibitor of Notch1 function in both in vitro and in vivo models. These data were presented today at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C.
› Verified 2 days ago